Reverse T3 (rT3)
For informational purposes only — not medical advice. Always consult a qualified healthcare provider before making changes to your health regimen. Full disclaimer →
- rT3 is the body's metabolic brake — it rises when the body needs to conserve energy, and its elevation impairs active T3 availability at the tissue level. The shift from T4-to-T3 conversion toward T4-to-rT3 conversion is a regulated physiological response to stress, illness, and starvation. In short-term acute situations this is adaptive. In chronic conditions — sustained cortisol elevation from chronic stress, chronic inflammatory states, prolonged caloric restriction, or persistent illness — elevated rT3 represents ongoing metabolic suppression that can produce functional hypothyroidism symptoms even with normal TSH.
- The FT3:rT3 ratio is a more sensitive marker of thyroid hormone efficiency than either value alone. Free T3 reflects active hormone availability; rT3 reflects the competing inactive fraction. Their ratio captures the balance between productive and unproductive T4 conversion. A person with FT3 of 3.5 pg/mL and rT3 of 25 ng/dL has a very different thyroid efficiency picture than someone with FT3 of 3.5 pg/mL and rT3 of 12 ng/dL — the same active hormone level, but the first person has far more T4 being diverted to an inactive pathway. The ratio integrates this competition.
- Elevated cortisol is the most common non-illness driver of elevated rT3 in otherwise healthy adults. Cortisol upregulates DIO3 (the enzyme that converts T4 to rT3) and downregulates DIO1 (which converts T4 to active T3). Chronic psychological stress, sleep deprivation, HPA axis dysregulation, and exogenous corticosteroid use all elevate cortisol and shift T4 conversion toward rT3. This is one mechanistic link between chronic stress and the constellation of fatigue, cognitive slowing, weight gain, and cold intolerance that many chronically stressed people experience — symptoms that can look like hypothyroidism because, at the tissue level, functional thyroid hormone availability is reduced.
- Severe caloric restriction dramatically elevates rT3. Very low calorie diets, prolonged fasting, and extreme caloric restriction consistently elevate rT3 and suppress active T3, reducing resting metabolic rate. This is a major mechanism of metabolic adaptation during weight loss — the body down-regulates metabolism by reducing T3 availability. The rT3 rise during caloric restriction can persist for weeks after refeeding, contributing to the metabolic rate suppression that makes sustained weight loss challenging. TSH typically remains normal throughout this process.
- The clinical utility of rT3 is strongest in patients with normal or borderline TSH and persistent hypothyroid symptoms. rT3 adds the least information in straightforward hypothyroidism (where TSH and FT4 are clearly abnormal) and the most information in the ambiguous middle zone — normal or borderline TSH, low-normal FT3, and symptoms that don't fully respond to standard treatment. In this scenario, an elevated rT3 confirms that conversion impairment is contributing to the functional hypothyroid state, pointing toward addressing the upstream drivers (cortisol, inflammation, selenium deficiency) rather than solely adjusting thyroid hormone doses.
The Metabolic Brake: Why the Body Makes Reverse T3
The production of reverse T3 is not a malfunction — it is a deliberately regulated process that serves an important purpose in the body's energy management system.
When resources are scarce or the body is under serious physiological threat — severe infection, starvation, major surgery, trauma — maintaining full metabolic rate is metabolically expensive and counterproductive. The body needs to redirect energy toward immune function, tissue repair, and survival rather than thermogenesis, protein synthesis, and high metabolic turnover. Reducing active T3 availability is one of the most efficient ways to lower metabolic rate quickly.
Type 3 deiodinase (DIO3) — the enzyme that converts T4 to rT3 instead of active T3 — is upregulated in liver, muscle, and other tissues under stress conditions. Simultaneously, the enzymes that produce active T3 (DIO1 and DIO2) are downregulated. The net result is a shift in the T4 conversion ratio: instead of the normal approximate split (40% to T3, 20% to rT3), under stress conditions the conversion can shift to 50% or more toward rT3, substantially reducing active T3 availability while keeping T4 and TSH relatively normal.
The problem arises when this acute stress adaptation becomes chronic. In a person with chronically elevated cortisol, persistent low-grade inflammation, or ongoing caloric deficit, the rT3-elevating conditions never resolve. The metabolic brake stays partially engaged, producing a state of functional tissue hypothyroidism that standard TSH-based testing will largely miss. 1
When rT3 Adds Clinical Information Beyond TSH and FT3/FT4
The standard thyroid assessment — TSH plus Free T4, sometimes Free T3 — captures pituitary-thyroid axis regulation and circulating free hormone levels. What it does not capture is the efficiency of peripheral T4-to-T3 conversion relative to rT3 production — the metabolic gateway that determines actual tissue thyroid hormone availability.
Measuring rT3 alongside FT3 and FT4 adds this dimension. The FT3:rT3 ratio integrates active hormone (FT3) against its inactive competitor (rT3) to reflect the balance of productive vs. non-productive T4 conversion. A low ratio means more T4 is being converted to an inactive compound that may actually compete with active T3 at receptor sites, while less is being converted to the active form.
| Metric | Concern Threshold | Longevity Optimal | Notes |
|---|---|---|---|
| Reverse T3 | > 20 ng/dL | < 15 ng/dL | Units vary by lab — verify before comparing |
| FT3:rT3 ratio | < 0.15 | > 0.20 | FT3 in pg/mL ÷ rT3 in ng/dL |
| Stable, healthy adult | FT3 3.2–4.0, rT3 <15, ratio >0.20 | Pattern confirms adequate conversion | |
| Range Type | Value (ng/dL) | Notes |
|---|---|---|
| Standard Clinical Range | 9.2–24.1 ng/dL (reference ranges vary significantly by laboratory and assay method) | Designed to identify disease risk — not longevity optimisation. |
| Longevity-Optimal Target | < 15 ng/dL · FT3:rT3 ratio > 0.20 (using pg/mL:ng/dL units) |
Associated with reduced all-cause mortality and extended healthspan.
rT3 reference ranges vary substantially between laboratories and assay methods — some use pg/mL, others ng/dL — making cross-lab comparison unreliable without unit conversion. The longevity-relevant target is less about the absolute rT3 value than about the FT3:rT3 ratio, which captures conversion efficiency. A ratio above 0.20 (when FT3 is in pg/mL and rT3 is in ng/dL) is generally considered adequate conversion; below 0.15 suggests meaningful conversion impairment. rT3 is very short-lived in the circulation (half-life approximately 4 hours), making it sensitive to acute changes — a single elevated value during or shortly after illness, surgery, or extreme stress may not represent a chronic pattern. Serial measurements under stable conditions are more informative than isolated readings.
|
Already have your results? See what your Reverse T3 (rT3) and other markers reveal about your longevity in 60 seconds.
Analyze My Labs →Affiliate disclosure: we may earn a commission if you purchase through these links at no extra cost to you.
How do I calculate the FT3:rT3 ratio from my lab results?
The FT3:rT3 ratio requires paying attention to units, as labs report these in different ways. The most common calculation uses Free T3 in pg/mL divided by Reverse T3 in ng/dL. If your Free T3 is 3.2 pg/mL and your rT3 is 20 ng/dL, the ratio is 3.2 ÷ 20 = 0.16. A ratio above 0.20 is generally considered adequate; below 0.15 suggests meaningful conversion impairment. However, unit inconsistency creates significant confusion — if your lab reports FT3 in pmol/L and rT3 in pmol/L, a different formula applies. Always confirm the units before calculating. If in doubt, the ratio calculation can be done with your clinician who can standardize units. The most important use of the ratio is tracking trends over time in the same individual under consistent conditions, not comparing absolute values against population references.
Should I test rT3 routinely, or only in specific situations?
Routine rT3 testing in asymptomatic people with normal TSH adds limited actionable information — the test is most useful in targeted clinical scenarios. The primary indication is persistent hypothyroid symptoms (fatigue, cold intolerance, cognitive slowing, weight gain, constipation) in someone with normal or borderline TSH, particularly when Free T3 is in the low-normal range. A second indication is a person who has had or is currently in a high-stress state — recent severe illness, surgery, significant caloric restriction, or high-intensity training load — where TSH may be misleadingly normal but functional T3 availability is reduced. A third indication is monitoring thyroid optimization in someone on T4-only replacement who has persistent symptoms despite normalized TSH and FT4, where elevated rT3 might explain incomplete response. For a routine annual longevity panel in a healthy, non-symptomatic person, Free T3 and Free T4 alongside TSH is usually sufficient.
Does elevated rT3 mean I should take T3 medication?
Not directly — elevated rT3 is a signal to investigate the upstream drivers, not an automatic indication for T3 supplementation. The appropriate response depends on why rT3 is elevated. If cortisol is driving the elevation (chronic stress, poor sleep, HPA dysregulation), addressing the cortisol burden — sleep optimization, stress reduction, adrenal support — is the primary intervention. If chronic inflammation is the driver (elevated hsCRP, IL-6), reducing inflammatory load through diet, exercise, and weight loss is appropriate. If selenium deficiency is impairing conversion, selenium repletion may improve FT3 without any thyroid medication. If severe caloric restriction is the cause, more moderate energy restriction with adequate protein allows rT3 to normalize. T3 supplementation (liothyronine) may be appropriate when upstream factors have been addressed and functional hypothyroidism persists — but this is a clinical decision requiring medical supervision, not a self-directed intervention based on a single lab value.
Is rT3 testing controversial among doctors?
Yes, the clinical utility of rT3 is genuinely debated in mainstream endocrinology. Most endocrinologists and standard clinical guidelines do not include rT3 in routine thyroid assessment, and the evidence base for adjusting thyroid treatment based on rT3 levels is weaker than for TSH and FT4. Critics note that rT3 is unstable (short half-life), assays vary between labs, reference ranges are not well-standardized, and there are limited randomized controlled trials demonstrating that rT3-guided treatment improves outcomes. Proponents argue that rT3 captures functional thyroid hormone availability that TSH misses, particularly in the context of chronic stress and illness, and that the FT3:rT3 ratio is clinically meaningful for identifying patients who may benefit from T3 supplementation. In longevity and functional medicine practice, rT3 is more commonly used than in conventional endocrinology. Understanding this debate allows appropriate framing of results — rT3 is a useful clinical signal, but one that requires interpretation alongside other markers and clinical context, not a standalone decision driver.